BCL2 and breast carcinoma: Our findings elucidate the potential synergistic mechanism between an HSP90 inhibitor BIIB021 and the BCL-2 family inhibitor ABT-263, pointing to the possibility of a more effective therapeutic approach for breast cancer treatment.